Clinical trial · Observational
Lung Tumour Volume Database
Tumour Volume as an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer - A Protocol for a Prospective Database.
NCT00351598CI-TRIAL-00015302completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main aim is to determine, in patients with locoregional, non-small cell lung cancer (NSCLC) treated by definitive radiotherapy, the influence on survival of the volume of primary tumour, as measured from CT imaging, after adjusting for the effect of the current TNM staging system and other known prognostic factors (especially ECOG performance and weight loss).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Definitive Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Patients with loco-regional, NSCLC treated by definitive radiotherapy.
- interventionNames
- Radiation: Definitive Radiotherapy
Primary outcomes (1)
- measure
- Survival
- timeFrame
- End of Study
- description
- Survival duration defined as the time from date of registration until death from any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Must satisfy ALL of the following * NSCLC - histological or cytological diagnosis of non-small cell lung cancer * Intra-thoracic disease - disease is confined to the primary site, with or without intrathoracic lymph nodes * CT planning - CT imaging of the thorax has been performed as part of the planning procedure * Definitive radiotherapy - it is planned to give definitive radiotherapy with or without chemotherapy (prior to, during or after radiotherapy). Definitive radiotherapy is defined as 60 Gy in 6 weeks, 50 Gy in 4 weeks or at least the equivalent of either of these. The size of each individual; fraction should not exceed 2.5 Gy. * Measurable disease - the primary tumour and nodes with maximum diameter greater than 1cm represent measurable disease Exclusion Criteria: A patient satisfying ANY of the following is ineligible * Symptomatic or radiological evidence of metastatic disease * Prior treatment for non-small cell lung cancer * Surgical resection is part of initial treatment * Palliative radiotherapy planned
References
Publications (1)
- RESULTBall DL, Fisher R, Burmeister B, Graham P, Joseph D, Penniment M, Krawitz H, Wheeler G, Poulsen M, Vinod S, McClure B. Stage is not a reliable indicator of tumor volume in non-small cell lung cancer: a preliminary analysis of the Trans-Tasman Radiation Oncology Group 99-05 database. J Thorac Oncol. 2006 Sep;1(7):667-72. PMID 17409934